We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Valirx Plc | LSE:VAL | London | Ordinary Share | GB00BLH13C52 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.20 | -5.80% | 3.25 | 3.20 | 3.30 | 3.45 | 3.25 | 3.45 | 495,968 | 12:19:29 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Medical Laboratories | 0 | -2.37M | -0.0262 | -1.24 | 2.93M |
Date | Subject | Author | Discuss |
---|---|---|---|
04/11/2021 22:47 | I am so sorry to hear that Humphries and it does put everything into perspective. My prayers are with your family tonight | tburns | |
04/11/2021 19:56 | Hi to everyone just to update you all on my granddaughter she passed late this afternoon, thanks for all the kind words over last couple of years | humphries1 | |
04/11/2021 18:46 | Because they will be worth twice that in the not to distant future- imo of course | ragnarr | |
04/11/2021 09:44 | Closed my trading shares here this morning. Have been in and out of VAL on the way up and was expecting far more from the deal. Unfortunately, I can't see any reason to hold short term now so have sold up. IF it goes back into the mid 20's I will buy back, but with no short term news to drive this, I can see it being sold into. Good luck all. | liam1om | |
04/11/2021 09:30 | but its very clear..Under this proposed Licence Agreement, TheoremRx will obtain a worldwide licence to ValiRx's VAL201 intellectual property for a novel peptide targeting SRC kinase targeting oncology indications. ValiRx will retain the rights to develop the VAL201 peptide for non-oncology indications, including VAL301 for endometriosis. Subject to successful market authorisation, the potential value of the deal would be in excess of US$61M plus royalties for the first cancer indication alone. Each oncology indication successfully developed to by TheoremRx will generate up to $37.5M of additional value to ValiRx. The proposed deal structure comprises payments on signature of the Licence Agreement plus fees and near-term milestones totalling US$2.2M before the end of 2023, milestones on further clinical and commercial development events, and royalties. The first payments are expected by the end of 2021. | ragnarr | |
04/11/2021 09:15 | Porkies post seemed honest and a genuine view. He did “ramp it” massively but seemed to believe his own valuation. What he said many times is “I don’t know Why…” “I don’t know why…” etc That’s the problem, isn’t it? We don’t know why this deal is being done. Suzy seems happy with it so it could still be massive or maybe her expectations are a lot lower than Porkies, because she does know why. | guss | |
04/11/2021 08:52 | It was only in imaginary heads that the deal was going to be with big pharma. The management never alluded to that. VAL201 is a legacy product that is now going to produce exceptional revenue. It just shows me that most punters here invest in headlines not facts. | ragnarr | |
04/11/2021 08:34 | This seems a very accurate analysis of the situation. It is very strange to announce the sale to an unfunded company with no clear links to Valrx. The market reaction is entirely understandable. | bonzo | |
04/11/2021 08:12 | People spiked over 40p | jaforsadi | |
04/11/2021 07:23 | This time Average please honour your statement not to post here again. Thank you. | uknighted | |
04/11/2021 07:05 | 🤡🐷 well done porky for posting I do honestly believe you I think val will trade 40’s for a while now and I know you wanted £ I myself have total respect for you and wish you well take care and no one is more dissapointed than you I understand that! Chin up and adios i to will not be posting here again! At 32p someone had to ramp as that was oversold! IMO! Adios all here xx | average down mug | |
04/11/2021 05:47 | This is my last post on here on Valirx as I’m not going bull to bear anytime soon as that is not my style. I still own some shares here but equally I don’t want individuals trolling me or accusing me of being a swing trader when I am not. The stock is not about me, you all need to Do Your Own Research and make your own calls. I research a company and stock to the best of my ability; I don’t put significant sums of my family money into a business at risk without doing so. I have worked hard to improve the profile of this company and bring awareness to it and interest is higher here as a result. I had totally brought into this company. The deal Valirx has proposed I don’t think is a good deal for shareholders but that is my own personal view, but I don’t know enough about it. This could be the deal of the century for all I know. Clearly some posters here love it so that’s great, I’m sure the stock will climb today as a result. I don’t know why Vali RX decided to hand over their prize asset to a US Start up Theorem RX I don’t know who is behind this business? is it related? Is this some sort of Val2 USA flavour? Are directors or key investors of Valirx involved in the set up of the stateside business? Can shareholders here buy shares in the raise? Is there a prospectus? Are Cenkos supporting the stateside raise? Is this why the business likes Cenkos? As i say I know nothing about this business or this arrangement and when I invest, I like that clarity. In time investors should know more and be able to make a more informed decision. I understand that Valirx are going to continue supporting the development of 201 for a token £20k a month and are now also going to continue the development of 301. I understand that Valirx will see $2.2m USD (£1.6m sterling?) over the next two years and this will ensure they don’t need an immediate placement. Milestone payments if/as they are reached but again no clarity of what those milestones are? Running costs at VAL are £350k a quarter currently so it will be tight. From my own personal view and its MY OWN view this was not the outcome I wanted. IMO this means that the business will remain bootstrap. I wanted to see a deal with a recognised brand, I wanted enough cash on the table not just to keep them trading but enough to given them the wiggle room to take on and fund loads of new projects to really drive the company forward for exponential growth. For me, the deal fell short of that and that is my honest precis of how I see the situation currently. Hopefully, once everything is fully known, as I say a more informed decision can be made. My remaining stock averages circa 25p. I am happy with that but won’t be adding at these levels but that’s my business. Sorry to disappoint. GLA | porky9 | |
03/11/2021 23:53 | Are you thick??? | aimmafia | |
03/11/2021 23:06 | Suzy sounds pretty sharp and confident. Helps to calm my nerves somewhat. | guss | |
03/11/2021 21:30 | surpised no one is talking about this tonight. https://audioboom.co | ragnarr | |
03/11/2021 17:30 | Ffs I only put £2k in relax 🤡☝A | average down mug | |
03/11/2021 17:20 | I honestly bought yesterday at 32 sold last week 57 I trade val and allways win !! Busy day tomorrow can you become 🐷👌 | average down mug | |
03/11/2021 17:16 | I sold changed my mind bought back 37 thankyou! I deserve a thank you for becoming 🐷 for a day it’s hard work you know!! Anyway did you see 20p na 39p 😁 | average down mug |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions